CUE Stock Performance, Insider Transaction and News

CUE - Cue Biopharma, Inc.

Market Cap	157.60M	P/E	-	EPS this Y	27.90%	Ern Qtrly Grth	-
Income	-46.96M	Forward P/E	-2.70	EPS next Y	27.50%	50D Avg Chg	-8.00%
Sales	8.29M	PEG	-	EPS past 5Y	-	200D Avg Chg	5.00%
Dividend	N/A	Price/Book	2.86	EPS next 5Y	-	52W High Chg	-29.00%
Recommedations	1.40	Quick Ratio	1.94	Shares Outstanding	60.21M	52W Low Chg	67.00%
Insider Own	0.55%	ROA	-52.11%	Shares Float	45.28M	Beta	1.96
Inst Own	23.06%	ROE	-138.87%	Shares Shorted/Prior	3.56M/3.66M	Price	3.65
Gross Margin	-	Profit Margin	-	Avg. Volume	465,509	Target Price	4.00
Oper. Margin	-390.63%	Earnings Date	Nov 7	Volume	408,001	Change	-3.44%

Healthcare | Biotechnology | United States

About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma, Inc. News

11/17/24	Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations
11/14/24	Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
11/14/24	Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/14/24	Cue Biopharma Announces Strategic Organizational Transition
11/12/24	Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
11/08/24	Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
10/08/24	Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%
10/04/24	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
09/26/24	Cue Biopharma Announces Pricing of $12.0 Million Public Offering
09/26/24	Cue Biopharma Announces Proposed Public Offering
09/09/24	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
09/03/24	Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
08/20/24	Q2 2024 Cue Biopharma Inc Earnings Call
08/19/24	Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/14/24	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
08/13/24	Cue Biopharma to Host Business Update Call and Webcast
07/26/24	Cue Biopharma downsizes to focus on autoimmune pipeline
07/25/24	Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
06:54 AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
06/04/24	Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

CUE Chatroom

Mastersushie1 Posted - 5 days ago

$CUE Biopharma’s early investors are losing money, and the management continues to believe they can play the long-run game without taking any meaningful action. It’s incredibly frustrating and damaging to shareholders. The company has good science and an opportunistic board, but after 7 years and millions of dollars burned, there’s been zero value creation. The CEO should be fired—he isn’t creating any value. What’s the strategy here? Collecting money from investors every couple of years just to pay their own salaries and bonuses, attending conferences to present the same data, and now jumping to another vertical. In 2030, we’ll still be in Phase 1 of CUE 800 immunotherapy while they’re excited to present ‘matured’ results from CUE 100. They’ll still be looking for partnerships, and some other foolish investors will finance their lifestyle. This isn’t about science anymore; it’s about protecting their own interests and timing for retirement while leaving shareholders in the dust.

Food_Bio_Boy Posted - 5 days ago

$CUE Long term holds will be the winners with this stock. Multiple strong programs, good safety, good science, protected position.

liloleme4 Posted - 6 days ago

$CUE Nice earnings report, coupled with forward looking plans

DonCorleone77 Posted - 6 days ago

$CUE Cue Biopharma reports Q3 EPS (17c), consensus (19c) Reports Q3 revenue $3.34M, consensus $1.52M. "We are very pleased with the validating updated clinical data from our Phase 1 trials for both CUE-101 and CUE-102," said Daniel Passeri, chief executive officer of Cue Biopharma. "Importantly, we believe the maturing data further supports and strengthens our competitive differentiation and positioning for selective modulation of disease-specific T cells. This data further bolsters our confidence that the CUE-100 series, exemplified by CUE-101 and CUE-102, represents the potential of establishing a new standard of care for cancer patients. We are also very pleased with the continued progress of our preclinical autoimmune programs, both of which have moved closer towards drug candidate selection."

ako13 Posted - 6 days ago

$CUE you may buy at 1.34 😁

TotalAmateur Posted - 1 week ago

$CUE is going to bleed down as traders take profits from last month. They must get a partner and launch phase 2 in CUE 101. The data is just too compelling to wait around.

TrendsetterTrading Posted - 1 week ago

$CUE Watch for the next leg up. Chart is stair stepping into resistance for a nice swing play opportunity. Support at $1.40

SpyVsSpy2 Posted - 1 week ago

$CUE is hiring…

Food_Bio_Boy Posted - 1 week ago

$CUE Presentations look great. Excited to see how they can ramp up phase 2 with Cue 102 and any potential partnerships on 101. hopefully both being worked on.

bestdriver77 Posted - 1 week ago

$CUE

DARKP00L Posted - 1 week ago

$CUE the market is buzzing about this stock. Expect possible price changes!

Food_Bio_Boy Posted - 1 week ago

$CUE Wow...

GreenhornInvest Posted - 2 weeks ago

$CUE is up this morning before market opening. Check it out.

TotalAmateur Posted - 2 weeks ago

$CUE I'm excited to see the new data on the poster which will be available tomorrow at 9am. The presentations are on Friday and Saturday and being led by two different doctors on the cancer research team at Moffitt.

Nerofin Posted - 2 weeks ago

$CUE is performing well again today

ako13 Posted - 2 weeks ago

$CUE need to break 1.87$

GreenhornInvest Posted - 2 weeks ago

Keep an eye on $CUE today!